Skip to main content
Premium Trial:

Request an Annual Quote

UNC Researcher Wins $100,000 NARSAD Grant

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A University of North Carolina at Chapel Hill researcher will use a grant from the National Alliance for Research on Schizophrenia and Depression (NARSAD) to study the genomes of four families that suffer from schizophrenia and bipolar disorders.

The $100,000, two-year Distinguished Investigator Award from NARSAD will support UNC School of Medicine researcher Patrick Sullivan in a comparison of the genetics of the two diseases in order to identify links to psychosis.

The research will focus on two families from northern Sweden and two others from Andalusia, in Spain. All of the families have an unusually high number of members affected with these disorders, and Sullivan will study the families to identify genetic variants and genetic copy number changes of interest.

Sullivan and his research team will then sequence the DNA from a subset of cases and compare any possible sequence variations with unrelated samples.

The aim is to identify genes associated with schizophrenia that will help improve diagnosis and treatments for disorders that have psychotic symptoms.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.